# JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme

> **NCT00311402** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1295 (actual)

## Conditions studied

- Cerebrovascular Accident

## Interventions

- **DRUG:** Aggrenox capsule
- **OTHER:** Acetylsalicylic Acid (ASA)

## Key facts

- **NCT ID:** NCT00311402
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2009-03
- **Final completion:** —
- **Target enrollment:** 1295 (ACTUAL)
- **Last updated:** 2014-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00311402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00311402, "JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00311402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*